Hla-a*0206 with tlr3 polymorphisms exerts more than additive effects in stevens-johnson syndrome with severe ocular surface complications

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ueta, Mayumi ^a,b   Tokunaga, Katsushi ^c   Sotozono, Chie ^a   Sawai, Hiromi ^c   Tamiya, Gen ^d   Inatomi, Tsutomu ^a   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; TOLL LIKE RECEPTOR 3; HLA A*02:06 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:06 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EYE DISEASE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HETEROZYGOTE; HLA A GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMORPHIC LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TLR3 GENE; TOXIC EPIDERMAL NECROLYSIS; GENETIC EPISTASIS; GENETICS; GENOTYPE; MIDDLE AGED; RISK;

ADULT; EPIDERMAL NECROLYSIS, TOXIC; EPISTASIS, GENETIC; EYE DISEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HLA-A2 ANTIGEN; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; STEVENS-JOHNSON SYNDROME; TOLL-LIKE RECEPTOR 3; YOUNG ADULT;

EID: 84865079063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043650     Document Type: Article

References (23)

1. Stevens AM, Johnson FC, (1922) A new eruptive fever associated with stomatitis and opthalmia: report of two cases in children. Am J Dis Child 24: 526-533.
2. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A, (2000) Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 83: 347-352.
3. Forman R, Koren G, Shear NH, (2002) Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 25: 965-972.
4. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333: 1600-1607.
5. Wolf R, Orion E, Marcos B, Matz H, (2005) Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23: 171-181.
6. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, et al. (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138: 1019-1024.
7. Yetiv JZ, Bianchine JR, Owen JA Jr, (1980) Etiologic factors of the Stevens-Johnson syndrome. South Med J 73: 599-602.
8. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS, (1995) Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 102: 1669-1676.
9. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, et al. (2009) Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 116: 685-690.
10. Ueta M, Kinoshita S, (2010) Innate immunity of the ocular surface. Brain Res Bull 81: 219-228.
11. Ueta M, Sotozono C, Nakano M, Taniguchi T, Yagi T, et al. (2010) Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol 126: 1218-1225 e1210.
12. Ueta M, Tamiya G, Tokunaga K, Sotozono C, Ueki M,et al. (in press) Epistatic interaction between TLR3 and PTGER3 confers an increased risk for Stevens-Johnson syndrome with ocular complications. J Allergy Clin Immunol.
13. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, et al. (2007) New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 114: 1294-1302.
14. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, et al. (2007) Association of IL4R polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol 120: 1457-1459.
15. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, et al. (2008) Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 92: 989-991.
16. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, et al. (2008) Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications. Invest Ophthalmol Vis Sci 49: 1809-1813.
17. Ueta M, Sotozono C, Inatomi T, Kojima K, Tashiro K, et al. (2007) Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 91: 962-965.
18. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S, (2007) Strong Association Between HLA-A*0206 and Stevens-Johnson Syndrome in the Japanese. Am J Ophthalmol 143: 367-368.
19. Ueta M, Tokunaga K, Sotozono C, Inatomi T, Yabe T, et al. (2008) HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 14: 550-555.
20. Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, Gao YY, et al. (2005) Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 112: 904-912.
21. Kawai T, Akira S, (2007) TLR signaling. Semin Immunol 19: 24-32.
22. Mondino BJ, Brown SI, Biglan AW, (1982) HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol 100: 1453-1454.
23. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, et al. (2010) HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51: 2461-2465.